Product category:
Nucleic acid sequencing and synthesis
News Release from: Applied Biosystems
Edited by the Laboratorytalk Editorial
Team on 06 January 2006
AB invests in VisiGen Biotechnologies
Applied Biosystems has agreed to invest in, and collaborate with, VisiGen Biotechnologies, a privately held next-generation sequencing technology company
VisiGen's technological approach to DNA sequencing is based on the ability to analyse a single molecule of DNA in real time, which has the potential to drastically reduce the cost of sequencing and significantly improve throughput compared to existing commercially available technologies Their solution could provide a quantum leap in the scope and scale of research aimed at uncovering the genetic basis of common diseases such as cancer, heart disease and diabetes
This article was originally published on Laboratorytalk on 2 Oct 2001 at 8.00am (UK)
Related stories
High throughput nucleic acid purification
Applied Biosystems has released the ABI Prism 6100 nucleic acid PrepStation for high throughput purification of RNA and DNA, taking only 30 minutes to isolate total RNA from cells
"Applied Biosystems continues to extensively evaluate potential next-generation sequencing technologies.
"We believe that the quality of VisiGen's science and the progress towards the development of single-molecule sequencing technology is quite impressive," explained Catherine Burzik, president of Applied Biosystems.
Susan Harding, president and CEO of VisiGen, continued: "VisiGen's approach of monitoring parallel arrays of single molecules could allow large-scale sequencing projects in the areas of cancer and other diseases and could make sequencing-based targeted medicine a reality.
"This investment by Applied Biosystems, and its expertise in DNA sequencing, makes it an ideal partner for us as we work towards commercialisation.".
• Applied Biosystems: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page

